3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
Gemcitabine
6
Trastuzumab
4
Carboplatin
3
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Cisplatin
2
vinflunine
1
tucatinib
1
relatlimab
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
apatorsen
1
abemaciclib
1
Zoledronic Acid
1
Urinary Diversion
1
Therapeutics
1
Thalidomide
1
Sunitinib
1
Radiosurgery
1
Nivolumab
1
Mitomycin
1
MART-1 Antigen
1
Immunoglobulins, Intravenous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urologic Neoplasms
×
niraparib
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts